FORT WASHINGTON, PA — Nabriva Therapeutics plc (NASDAQ: NBRV) announced that it recently entered into an Exclusive Distribution Agreement with Er-Kim, a leading partner for biotech companies in international markets, for the oral and intravenous formulations of XENLETA (lefamulin).
Under the terms of the agreement, Er-Kim gains exclusive rights to distribute XENLETA in the following countries: Bulgaria, Croatia, Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia. Er-Kim also may distribute XENLETA to an additional five countries through a Named Patient Usage (NPU) program. Nabriva will be the exclusive supplier of XENLETA to Er-Kim.
Ted Schroeder, Chief Executive Officer of Nabriva Therapeutics, commented, “We are excited to partner with Er-Kim, whose local expertise and proven track record uniquely position them for success in making XENLETA available to patients in these territories with community acquired bacterial pneumonia (CABP). We look forward to working with Er-Kim as a valued distribution partner to broaden the availability of XENLETA outside the U.S.”
Cem Zorlular, Chief Executive Officer of Er-Kim, added, “We are thrilled to partner with Nabriva to bring XENLETA to a region where there is a significant unmet need for patients with CABP. We feel privileged to work with Nabriva, who shares our passion in addressing patients’ unmet needs in serious infections.”
Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.